Cipla Limited

CIPLA

INE059A01026

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).

Sector

Pharmaceuticals

Calendar

2024-02-06 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cipla Limited

Trading Rating :

Investor Rating :

ESG Refinitiv :

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,219.1INR

Average target price

1,260.46INR

Spread / Average Target

+3.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CIPLA LIMITED	+13.30%	11 845 M $
SUN PHARMACEUTICAL INDUSTRIES LTD.	+23.41%	35 676 M $
OTSUKA HOLDINGS CO., LTD.	+29.69%	21 567 M $
SANDOZ GROUP AG	0.00%	12 892 M $
ONO PHARMACEUTICAL CO., LTD.	-17.27%	8 617 M $
ZYDUS LIFESCIENCES LIMITED	+52.05%	7 990 M $
THE MEDICINES COMPANY	-0.05%	6 788 M $
STADA ARZNEIMITTEL	-8.87%	5 726 M $
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.70%	4 981 M $
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.	+48.67%	4 919 M $

Generic Pharmaceuticals

Market Closed - NSE India Stock Exchange Other stock markets 06:43:29 2023-12-08 am EST			5-day change	1st Jan Change
1,219.1 ^INR	-0.30%		+0.56%	+13.30%

Nov. 27	Cipla's Arm Acquires Additional 15% Stake in Joint Venture	MT
Nov. 24	Selling in IT Drags Indian Equities to Close Lower on Friday	MT

Cipla's Arm Acquires Additional 15% Stake in Joint Venture	Nov. 26	MT
Selling in IT Drags Indian Equities to Close Lower on Friday	Nov. 24	MT
INDIA STOCKS-Indian shares lacklustre as IT stocks snap rally	Nov. 23	RE
Indian Equities End Flat on Thursday, Weighed Down by Pharmaceutical, IT Stocks	Nov. 23	MT
Gains in Domestic Major Companies Push Indian Equities to Close Higher on Wednesday	Nov. 22	MT
Cipla Gets Warning Letter from US FDA After Pithampur, India Unit Inspection	Nov. 19	MT
INDIA STOCKS-Indian shares set for muted opening; TCS, Cipla in focus	Nov. 19	RE
Cipla Completes Sale of Entire Stake in Ugandan Subsidiary	Nov. 15	MT
India's Zydus Q2 profit jumps on strong domestic, US demand	Nov. 07	RE
India's Gland Pharma misses Q2 profit view on higher expenses	Nov. 06	RE
Nomura Adjusts Cipla's Price Target to INR1,353 from INR1,229, Keeps at Buy	Oct. 30	MT
Jefferies Downgrades Cipla to Hold From Buy, Adjusts Price Target to INR1,230 From INR1,210	Oct. 30	MT
Cipla's Consolidated Net Profit Climbs in Fiscal Q2	Oct. 30	MT
INDIA STOCKS-Financials lead slide in Indian shares; Reliance curbs losses	Oct. 30	RE
Transcript : Cipla Limited, Q2 2024 Earnings Call, Oct 27, 2023	Oct. 27	CI
Indian drugmaker Cipla tops Q2 profit view on strong demand	Oct. 27	RE
Cipla Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Oct. 27	CI
Cipla Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Oct. 27	CI
Indian Equities End Lower for Fifth Straight Session on Israel-Hamas Conflict Worries	Oct. 25	MT
Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences	Oct. 24	CI
Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative	Oct. 23	CI
India's Torrent Pharma posts Q2 profit rise on strong demand	Oct. 23	RE
Indian Equities Fall on Wednesday Amid Intensifying Israel-Hamas Conflict	Oct. 18	MT
Cipla Arm Gets US FDA's Establishment Inspection Report After Inspection of New York Unit	Oct. 11	MT
Family Rift Clouds $7 Billion Sale of Cipla	Oct. 10	CI